Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Women-specific Illness Vivien Tsu, PhD MPH Determinants of Women’s Health Biological: Social: • pregnancy/delivery • poverty • unwanted pregnancy • lower status • conditions aggravated by pregnancy • less education • infections • seclusion rules • reproductive cancers • gender roles Deciding on Action • Magnitude and seriousness of problem, i.e. disease burden • Affected groups • Causes • Feasible interventions Burden of disease in women aged 1544 in developing countries Injuries 12% Cardiovascular disease 6% Other noncommun. dis. 14% Malnutrition 6% Depression/psy chiatric 12% Maternal causes 18% STDs & AIDS 16% Tuberculosis 7% Other commun. Disease 9% Source: Tinker, IJGO 70:149-58, 2000. (based on World Bank DALYs, 1993) Cervical Cancer Cervical Cancer Incidence, 2008 North America 12,491 Europe 54,517 Central and South America 63,487 Asia 312,990 Africa 80,419 Numbers indicate cases per 100,000 population Source: Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr Another way to look at it www.worldmapper.org (2002) Why is the burden so high in low-resource countries? • ~490,000 cases; ~270,000 deaths each year • >80% in developing countries • Expected to increase to >775,000 new cases by 2030, with >99% of deaths in developing countries • No organized screening programs, despite many efforts • “Competing” health problems • Prevalence of high-risk HPV infection higher • Limited awareness of cost-effective approaches to prevention • Until recently, no vaccine available to prevent infection HPV Infection & Cervical Cancer • HPV is a necessary but insufficient cause of cervical cancer • 99.7% of cervix cancer cases associated with HPV • Human papillomavirus (HPV) is a very common STI (more than 50% of adults get it) • Most HPV+ women do not develop cervical cancer • Two HPV types—16 and 18—account for 70 percent of cervical cancer cases (though regional variations exist) • Progression from HPV infection to cancer usually takes 20–30 years How cervical cancer develops Long latent period allows screening to detect precancer Source: Wright, TC and Schiffman, M. Adding a Test for Human Papillomavirus DNA to Cervical-Cancer Screening. The New England Journal of Medicine 2003;348:489-490. Opportunities for Screening • Visible pre-cancerous lesion • Long development of pre-cancer stage (10-15 years) • Despite different rates, age pattern is consistent - peak in pre-cancer in 30s and 40s Why hasn’t cytologic screening (Pap testing) worked for low-income areas? • Low sensitivity and limited reproducibility • Requires frequent visits and high coverage • Requires quality controls and regular training • Global costs of programs are very high IARC MONOGRAPH: SCREENING FOR CERVICAL CANCER 2005 Potential cervical cancer screening methods in low-resource settings Visual inspection with acetic acid (VIA) Conventional pap Visual inspection with Lugol’s iodine (VILI) careHPV (QIAGEN) Hybrid Capture® 2 (hc2, QIAGEN) Visual Inspection with Acetic Acid (VIA) • Cervix washed with vinegar (3-5% acetic acid) and inspected with naked eye 1 minute later • HPV-infected cells contain more proteins, which vinegar coagulates and causes to appear more opaque (acetowhite) than nearby normal tissues • 5-day curriculum for nurses and midwives • Equipment and supplies: speculum, cotton swabs, vinegar, lamp or torch • Immediate results • ~31,000 women screened with VIA, ~30,000 in control group • Incidence of cervical cancer ~25% lower, and mortality ~35% lower • 38% reduction in incidence and 66% lower mortality among women 30-39 (Lancet, 2007) VIA and Low-resource Settings • VIA is better than Pap smear for identifying high-grade CIN - especially if testing is only once in a lifetime • VIA is simple to perform and provides an immediate result without expensive equipment • Possible to link confirmation/treatment to screening visit • Healthcare provider can be trained in one week A new HPV DNA test for low-resource settings START project: -Developed the new test. hc2 -Validated it with specimens from China and India. QIAGEN: -Set up production in China. The careHPVTM test -Seeking regulatory approval in China. Cryotherapy: Simple Treatment • Metal probe applied to the cervix to freeze (-50o C) the abnormal area for total of 6 minutes • Does not require electricity; uses low-cost CO2 or NO2 gas • 80-90% effective in ablating even high-grade precancerous lesions (CIN 2 or 3) • Ideal for nurses to perform at district hospitals and maybe even in health centers • Appropriate for most lesions, except very large ones and those involving the canal Promising Preventive Option • 2 new vaccines: Merck Gardasil; GSK Cervarix • HPV vaccines are prepared from virus-like particles (VLPs) using recombinant technology • They are non-infectious • Current HPV vaccines are designed to protect against HPV 16 and 18; one also protects against low-risk types 6 and 11 • The vaccines are highly effective and safe • They provide protection for at least 6 years, likely much longer Current HPV VLP vaccines Vaccine Type Licensure status Gardasil (Merck) Cervarix (GSK) HPV 6/11/16/18 HPV 16/18 Licensed in > 120 countries Licensed in > 80 countries Girls/Women age 9–26 Target groups (age varies by country) Girls/Women age 10–55 Boys 9–15 (Europe, Australia, Mexico, others) Clinical trials Schedule ~21,000 ~27,000 0-, 2-, 6-months 0-, 1-, 6-months Getting ready in 4 countries India Uganda Peru Vietnam Room for cautious optimism? Acceptance high in all 4 countries (75-95%) Positive support from parents, communities, and leaders No serious adverse events High completion of 2nd and 3rd doses Peru has now joined 32 other countries Challenges for the vaccine • Financing • GAVI funding on hold because of economic crisis • But price has already dropped from $120/dose in US and Europe to <$20-30 in Asia and Latin America • Countries need to pay delivery costs while also introducing other new vaccines • New platforms for delivery (schools, community outreach) • Evaluating impact (time lag, technical difficulties) Breast cancer – on the rise • 269,000 deaths in developing countries • Women living longer • Changing reproductive patterns • Increasing obesity and smoking • Again, inadequate services for detection and treatment; fear and stigma • Breast Health Global Initiative, developed resourcespecific guidelines http://www.fhcrc.org/science/phs/bhgi/ Indoor air pollution Chimney woodstove in Guatemala (SmithSivertsen et al, Am J Epid 2009) • New stove vs. open fire among rural Mayan women (n=504) • After 18 months, significantly fewer respiratory symptoms (RR=0.42) and 61.6% less carbon monoxide exposure Anemia Iron supplements and deworming in Vietnam (Phuc et al, BMC Public Health, 2009) • Women 15-45 received weekly iron-folic acid supplements and periodic deworming • Delivered by village health workers as part of regular care, achieved 85% coverage (full or partial compliance) • After 12 months, anemia dropped from 37.5% → 19.3%, hookworm infection dropped from 76.2% → 23.0% Emergency Contraceptive Pills (ECPs) ECPs: Health Need • 75 million women experience unintended pregnancy annually • 8 to 30 million women experience contraceptive failure annually • 36 million developing country women have an abortion each year • 20 million unsafe abortions occur annually --19 million in developing countries What is Emergency Contraception? • Emergency Contraceptive Pills (ECPs) • Often referred to as “the morning-after pill” • Birth control pill hormones taken in high dose within 3 days (72 hours) of unprotected sex • IUD Insertion • Within 5 days (120 hours) of unprotected sex • Can also be a long-term contraceptive method • Safe for women and for fetuses ECP Mechanism of Action • Clinical studies have shown that ECPs can inhibit or delay ovulation • Evidence regarding endometrial alterations equivocal - Not clear that changes observed would inhibit implantation • Biologic plausibility regarding inhibition of fertilization - Thickening of cervical mucous - Alterations in tubal transport of sperm or egg Source: Swahn et al., 1996, Ling et al., 1979, Rowlands et al., 1983, Ling et al., 1983, Kubba et al., 1986, Taskin et al., 1994 Effectiveness: Single-Use Progestin Only 100 women have unprotected sex in the 2nd or 3rd week of their cycle 8 will become pregnant without emergency contraception 1 will become pregnant using progestin ECPs (89% reduction) Source: Lancet, 1998. Common EC Misperceptions • ECPs are abortion pills Not true • Widespread ECP availability will • encourage irresponsible behavior Not true • encourage adolescent sexual activity Not true • reduce men’s willingness to use condoms • reduce reliance on other methods Not true Not true Outreach Mechanisms Client Materials Women’s Health Websites • www.rho.org (for info on cervical cancer and in the Archives tab other RH issues, e.g. contraception, RTIs, gender violence) • www.path.org/cervicalcancer • http://www.path.org/files/RH_ec_toolkit.pdf (for EC toolkit) • www.who.int/reproductive-health/ • www.reproline.jhu.edu/index.htm • www.guttmacher.org • www.who.int/gender/women_health_report/en/ Vivien Tsu, PhD, MPH Associate Director, Reproductive Health [email protected]